Brigatinib

Mecanismo de acción

Brigatinib is a type of cancer drug known as an ALK (anaplastic lymphoma kinase) inhibitor. It works by blocking the activity of ALK, a protein that is often over-expressed in certain types of cancer cells, such as non-small cell lung cancer (NSCLC).

The over-expression of ALK leads to uncontrolled cell growth and division, which is a hallmark of cancer. Brigatinib interferes with the activity of ALK by binding to the ALK protein and preventing it from interacting with other proteins that are essential for cell survival and proliferation.

By inhibiting the activity of ALK, brigatinib can help to slow the growth and spread of cancer cells. This can lead to a reduction in the size of tumors and an improvement in overall cancer symptoms.

It is important to note that the mechanism of action of brigatinib may vary depending on the type and stage of cancer being treated. The use of brigatinib should be guided by the recommendations of a healthcare provider who is familiar with the patient's medical history and current condition.

Indicación

Brigatinib is a medication that is used to treat a type of cancer known as non-small cell lung cancer (NSCLC). Specifically, it is indicated for the treatment of patients with ALK (anaplastic lymphoma kinase) positive NSCLC who have progressed on or are intolerant to crizotinib.

ALK positive NSCLC is a subtype of NSCLC that is characterized by a genetic alteration in the ALK gene. This alteration leads to the over-expression of ALK, which drives the growth and spread of cancer cells.

Brigatinib works by inhibiting the activity of ALK, which helps to slow the growth and spread of cancer cells. By doing so, it can help to reduce the size of tumors and improve overall cancer symptoms.

It is important to note that the use of brigatinib should be guided by the recommendations of a healthcare provider who is familiar with the patient's medical history and current condition. The drug should only be used in patients with ALK positive NSCLC, as its safety and efficacy have not been established in other types of cancer.

Experiencia de Dr. Reddy

Con sede en Hyderabad, India, Dr. Reddy's Laboratories es uno de los principales proveedores de ingredientes farmacéuticos activos (API) a nivel mundial. El negocio API de Dr. Reddy es considerado como un socio preferido de las compañías farmacéuticas en los Estados Unidos, Europa, Brasil, América Latina, Japón, China, Corea y los mercados emergentes.

El negocio de API de Dr. Reddy se nutre de las fortalezas técnicas profundas establecidas en los últimos 30 años en el desarrollo y fabricación de API complejas como esteroides, péptidos, moléculas complejas de cadena larga y API altamente potentes (HPAPI / medicamentos oncológicos). Esta experiencia se complementa con nuestra destreza en propiedad intelectual y asuntos regulatorios que nos ayudan a cumplir y superar los estándares regulatorios de manera consistente. Los APIs de Dr. Reddy´s Brigatinib es el resultado de la amplia experiencia en R&D, IP y Normatividad Aplicable.

Un componente clave para ayudar a nuestros clientes a ser los primeros en comercializar es una cadena de suministro receptiva. Logramos esto al asegurarnos de que todas nuestras instalaciones funcionen de manera eficiente y con los últimos estándares de calidad, seguridad y productividad. Una fuerte interconexión entre las empresas y las fábricas permite una reacción rápida a los cambios dinámicos del mercado, de modo que podamos evitar la escasez y satisfacer los repentinos aumentos de la demanda.